Ro shifts from visits to pathways

Ro became more valuable when it stopped selling a quick online prescription and started packaging a full medication workflow. In erectile dysfunction, the telehealth visit could be free because the money came from monthly drug fulfillment, but in GLP-1s and other protocol heavy categories the real work is everything after intake, labs, dose changes, side effect monitoring, and renewal. That turns care into a recurring operating system, not a one off consult.1 2 3 4

• Ro’s early products worked like a lightweight marketplace. A patient answered questions, a clinician reviewed, and generic medication shipped. That model scaled fast, but it also produced high churn because generic ED drugs were easy to substitute and the patient relationship stayed transactional.1 3
• GLP-1 care changed the product shape. Ro Body added a monthly subscription around ongoing obesity management, and Ro built or bought pieces like home phlebotomy, diagnostics, fertility testing, a lab, and pharmacies so one care loop could run from eligibility through refill inside one system.2 3
• This is also how Ro differs from adjacent players. Hone has stronger retention because testosterone therapy needs recurring labs and dose adjustment. Noom pairs GLP-1 access with tracking and coaching. The winning product is not the visit, it is the condition specific program wrapped around the drug.2 4

The next phase is a race to prove that pathway management deserves its own margin. As drug access gets cheaper and easier, Ro’s advantage will come from owning adherence, monitoring, and outcomes across obesity, fertility, and other repeat care categories where patients need an ongoing clinical loop, not just a prescription.2 3 4